HC Wainwright Lowers Fractyl Health (NASDAQ:GUTS) Price Target to $8.00

Fractyl Health (NASDAQ:GUTS) had its price objective dropped by research analysts at HC Wainwright from $9.00 to $8.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s target price would suggest a potential upside of 497.01% from the stock’s current price.

Several other equities research analysts have also commented on GUTS. LADENBURG THALM/SH SH assumed coverage on Fractyl Health in a research note on Thursday, August 28th. They set a “buy” rating and a $3.60 price target on the stock. Canaccord Genuity Group reduced their price objective on Fractyl Health from $12.00 to $6.00 and set a “buy” rating for the company in a report on Thursday, August 14th. Four equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $6.90.

Fractyl Health Stock Performance

NASDAQ:GUTS opened at $1.34 on Friday. The firm’s fifty day simple moving average is $1.20 and its 200-day simple moving average is $1.43. The company has a quick ratio of 1.22, a current ratio of 1.22 and a debt-to-equity ratio of 4.61. The stock has a market cap of $67.39 million, a PE ratio of -0.65 and a beta of 1.55. Fractyl Health has a fifty-two week low of $0.83 and a fifty-two week high of $3.48.

Fractyl Health (NASDAQ:GUTS) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.16). Fractyl Health had a negative net margin of 73,864.52% and a negative return on equity of 584.35%. Analysts expect that Fractyl Health will post -1.61 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Fractyl Health

A number of large investors have recently bought and sold shares of the business. Nuveen Asset Management LLC grew its holdings in shares of Fractyl Health by 61.5% during the fourth quarter. Nuveen Asset Management LLC now owns 72,958 shares of the company’s stock valued at $150,000 after purchasing an additional 27,778 shares during the last quarter. Jane Street Group LLC increased its position in Fractyl Health by 125.8% in the fourth quarter. Jane Street Group LLC now owns 22,700 shares of the company’s stock worth $47,000 after buying an additional 12,648 shares during the period. Bank of New York Mellon Corp lifted its stake in Fractyl Health by 54.5% in the first quarter. Bank of New York Mellon Corp now owns 64,020 shares of the company’s stock valued at $76,000 after buying an additional 22,572 shares during the last quarter. Nuveen LLC acquired a new position in shares of Fractyl Health during the first quarter valued at $87,000. Finally, HighTower Advisors LLC grew its position in shares of Fractyl Health by 57.9% during the first quarter. HighTower Advisors LLC now owns 40,921 shares of the company’s stock worth $49,000 after acquiring an additional 15,000 shares during the last quarter.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.